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myo-Inositol (inositol) is an essential nutrient that is used for building phosphatidylinositol and its
derivatives in eukaryotes and even in some eubacteria such as the mycobacteria. As a
consequence, fungal, protozoan and mycobacterial pathogens must be able to acquire inositol in
order to proliferate and cause infection in their hosts. There are two primary mechanisms for
acquiring inositol. One is to synthesize inositol from glucose 6-phosphate using two sequentially
acting enzymes: inositol-3-phosphate synthase (Ino1p) converts glucose 6-phosphate to inositol
3-phosphate, and then inositol monophosphatase (IMPase) dephosphorylates inositol 3-
phosphate to generate inositol. The other mechanism is to import inositol from the environment via
inositol transporters. Inositol is readily abundant in the bloodstream of mammalian hosts, providing
a source from which many pathogens could potentially import inositol. However, despite this
abundance of inositol in the host, some pathogens such as the bacterium Mycobacterium
tuberculosis and the protist parasite Trypanosoma brucei must be able to make inositol de novo in
order to cause disease (M. tuberculosis) or even grow (T. brucei). Other pathogens such as the
fungus Candida albicans are equally adept at causing disease by importing inositol or by making it
de novo. The role of inositol acquisition in the biology and pathogenesis of the parasite
Leishmania and the fungus Cryptococcus are being explored as well. The specific strategies used
by these pathogens to acquire inositol while in the host are discussed in relation to each
pathogen’s unique metabolic requirements.
Introduction
In order to cause an infection, microbes must be able to live
and proliferate inside the host. This necessitates the
acquisition of essential nutrients by the pathogen. The
pathogen must eitherobtainthese nutrientsfromthehost or
synthesize the nutrients de novo from more basic com-
pounds. The biosynthesis of phospholipids is an area that
has received considerable attention in terms both of the
insight it may give us regarding host–pathogen interactions
and the possibility that an understanding of phospholipid
metabolism may help in the identification of new drug
targets (Vial et al., 2003). Phospholipids are complex
molecules that are essential for membrane integrity and
intracellular signalling. The biosynthesis of these com-
pounds requires a complex ordered set of biochemical steps
involving a number of enzymes (Greenberg & Lopes, 1996;
van Meer et al., 2008; Vance, 2003; Vial et al., 2003). An area
of particular interest is understanding how pathogens
acquire basic molecules such as myo-inositol, serine, choline
or ethanolamine for the synthesis of phospholipids (Vial
et al., 2003). This review will focus on mechanisms used by
diverse pathogens to obtain myo-inositol for the synthesis of
the phospholipid phosphatidylinositol (PI).
In the last several years a number of studies have been
performed to elucidate the roles that proteins involved in
myo-inositol acquisition play in controlling virulence and/
or viability in a variety of different pathogens (Chen et al.,
2008; Martin & Smith, 2005, 2006a; Movahedzadeh et al.,
2004). This review will cover the fascinating repertoire of
mechanisms used by these different pathogens to acquire
myo-inositol.
Inositol
myo-Inositol is a precursor for making PI, which is
essential in all eukaryotes, including pathogenic fungi and
protozoa, as well as in a small, but very significant group of
eubacterial pathogens that includes the mycobacteria
(Michell, 2008). In order to synthesize PI the pathogen
must obtain myo-inositol. There are two main mechanisms
for acquiring this molecule: synthesizing it de novo from
glucose 6-phosphate or importing it from the host
(Majumder et al., 1997; Michell, 2008; Drew et al., 1995;
Einicker-Lamas et al., 2000, 2007; Jin & Seyfang, 2003).
myo-Inositol is a polyol that is characterized as a six-carbon
ring where each carbon is hydroxylated. A number of
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common (Majumder et al., 1997; Michell, 2008). For the
purposes of this review, myo-inositol will be referred to
simply as inositol.
In eukaryotes inositol is used to make PI, which serves as a
structural component of the membrane, but also as a
precursor for several other very important lipid molecules
including sphingolipids, ceramides and glycosylphosphati-
dylinositol (GPI) anchors (Michell, 2008). GPI anchors are
used to attach a number of proteins to the plasma
membrane and are essential in eukaryotic microbes
(Ferguson et al., 1994; Orlean & Menon, 2007). Certain
GPI-anchored proteins play a special role in the virulence
of both fungal and protozoan pathogens, serving as
adhesins and/or variable epitopes to evade the immune
system (Ferguson et al., 1994; Sundstrom, 2002). PI is also
the precursor for a wide variety of membrane-bound and
non-membrane-bound phosphorylated inositol signal-
transduction molecules (Michell, 2008; Strahl & Thorner,
2007). In addition, inositol serves as a ‘compatible
osmolyte’ in some metazoan cell-types such as kidney
and brain cells (Burg, 1997; Fisher et al., 2002).
Mycobacteria are one of the few groups of eubacteria where
PI is found in the membrane. PI serves as a precursor for
the generation of more complex glycolipids that compose
the outer cell wall of mycobacteria (Michell, 2008; Nigou et
al., 2003). In addition, the mycobacteria, along with other
actinomycetes, use inositol to generate a thiol compound
called mycothiol that serves many of the same functions as
glutathione in other organisms, including detoxification
and protecting the cell from oxidative damage (reviewed by
Newton & Fahey, 2002).
Most eubacteria besides the Actinomycetes do not utilize
inositol in their lipid membranes or as a redox molecule.
However, a number of bacteria such as Bacillus subtilis
(Yoshida et al., 1997, 2008), Aerobacter aerogenes (Berman
& Magasanik, 1966), Rhizobium leguminosarum bv. viciae
(Fry et al., 2001), Sinorhizobium meliloti (Galbraith et al.,
1998), Corynebacterium glutamicum (Krings et al., 2006)
and Lactobacillus casei (Yebra et al., 2007) can utilize
inositol as a carbon source. Even some microbial
eukaryotes (such as Cryptococcus species) have been shown
to use inositol as a carbon source (Healy et al., 1977).
De novo biosynthesis of inositol
The de novo generation of inositol occurs by a universal
mechanism that is conserved from eubacteria to archaea to
eukaryotes (Majumder et al., 1997). It depends on the
tandem action of two enzymes. The first enzyme is
inositol-3-phosphate synthase, which was first cloned from
Saccharomyces cerevisae and was called Ino1p (Donahue &
Henry, 1981), a name which will be used throughout this
review. This enzyme, which converts glucose 6-phosphate
to inositol 3-phosphate via a cyclization reaction, con-
stitutes the rate-limiting step in de novo synthesis. NAD
+
serves as both a hydrogen acceptor and donor so no net
NADH is formed in this reaction (Majumder et al., 1997).
The second enzyme in inositol synthesis is an inositol
monophosphatase (IMPase), which dephosphorylates ino-
sitol 3-phosphate to create inositol (Michell, 2008). In S.
cerevisiae, two redundant phosphatases, ScInm1p and
ScInm2p, serve this purpose (Lopez et al., 1999). The
inositol synthesized by the sequential action of these
enzymes can then be used to generate inositol-containing
compounds such as PI or mycothiol that, in turn, can be
used to make more complex molecules, depending on the
organism.
Imported inositol
The alternative mechanism for obtaining inositol is to
import it from the environment via inositol transporters.
The two main types of transporters found in both metazoa
and microbes are Na
+-o rH
+-linked cotransporters,
which both rely on ion gradients to transport inositol into
cells against concentration gradients. In humans, SMIT1
and SMIT2 encode Na
+/inositol symporters (Coady et al.,
2002; Kwon et al., 1992), and HMIT encodes a H
+/inositol
symporter (Uldry et al., 2001). A few inositol transporters
have been characterized in human pathogens. For example,
Trypanosoma cruzi has at least two different transporters
based on a biochemical analysis of import activities,
although neither transporter has actually been cloned.
One transporter activity is Na
+-linked and the other is not
(Einicker-Lamas et al., 2000, 2007). In contrast to the case
in T. cruzi, Leishmania donovani and Candida albicans have
only one inositol transporter each, and in both cases the
transporter is a H
+-linked symporter (Drew et al., 1995;
Jin & Seyfang, 2003). Inositol transporter activity has also
been identified in the bacterial pathogen Mycobacterium
tuberculosis as well as the environmental species
Mycobacterium smegmatis. Although putative transporter
genes have been identified bioinformatically in both M.
tuberculosis and M. smegmatis, these genes have not yet
been experimentally linked to transport activities by gene
disruptions or transport assays (Movahedzadeh et al., 2004;
Newton et al., 2006).
Mycobacterium species
In the pathogenic bacterium Mycobacterium tuberculosis,
disruption of the inositol phosphate synthase gene MtINO1
ablated the ability of the pathogen to cause disease in a
mouse model of infection (Movahedzadeh et al., 2004).
The ability of M. tuberculosis to grow within macrophages
is essential to virulence. Experiments done in tissue culture
macrophages revealed that the Mtino1D mutant was killed
more efficiently by macrophages than the wild-type strain
(Movahedzadeh et al., 2004). Thus, these results indicate
that M. tuberculosis needs to generate inositol de novo in
order to survive in a macrophage and cause disease, and
cannot compensate by importing inositol from the host.
This is not because M. tuberculosis lacks the ability to
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import inositol is not efficient. The Mtino1D mutant can
only grow at wild-type rates on medium containing high
inositol concentrations (¢77 mM, Fig. 1a). It grows
poorly in medium containing 10 mM inositol and not at
all in medium with 1 mM inositol (Movahedzadeh et al.,
2004). The concentration of inositol in human serum is
61.0±12.4 mM and in rats it is 20–100 mM (Isaacks et al.,
1997; Kouzuma et al., 2001; Palmano et al., 1977), which
suggests that there is an insufficient concentration of
inositol to support growth of the Mtino1D mutant while it
is in the host.
The 77 mM inositol concentration required to support
growth of the Mtino1D mutant is very high when compared
to other organisms. For example, an S. cerevisiae Scino1D
mutant can grow on 10 mM inositol (Graves & Henry,
2000), and an Msino1D mutant of the environmental
mycobacterium M. smegmatis can grow on 1 mM inositol
(Fig. 1a) (Alderwick et al., 2007; Haites et al., 2005). The
fact that the Mtino1D mutant requires such high concen-
trations of inositol suggests that it does not carry a true
inositol transporter, but rather a sugar transporter that can
also transport inositol at low efficiency. This question can
be addressed when this transporter is cloned and
characterized.
The reasons why the Mtino1D mutant is not virulent in
mice and loses viability in macrophages are not clear. This
is in part because there are conflicting data on which
downstream inositol-containing molecules are affected by
inositol depletion and what role these molecules have in
virulence. There are two main types of molecules
synthesized from inositol that affect growth and/or
virulence characteristics. One molecule is PI, which is used
to make inositol-containing lipoglycans such as phospha-
tidylinositol mannoside (PIM), lipomannan (LM) and
lipoarabinomannan (LAM) that localize to the waxy
envelope. The other molecule is mycothiol, which is used
for redox chemistry (Alderwick et al., 2007; Nigou et al.,
2003; Rawat & Av-Gay, 2007).
PI and PIM are required for viability, and LAM modulates
the immune response in a manner required for virulence.
LAM blocks maturation of the phagosome, which is
important for M. tuberculosis to survive in the macrophage
(reviewed by Briken et al., 2004).
It is clear that PI, PIM and LAM are required for virulence;
however, it is not clear if inositol depletion in the Mtino1D
mutant causes a deficiency in their production. Analysis of
the cell envelope of the Mtino1D mutant after incubation in
inositol-free medium revealed that the mutant did not
Fig. 1. Loss of the MtINO1 gene in Mycobacterium tuberculosis
causes a loss of viability and mycothiol in inositol-free media. It is
unclear if the Mtino1D mutant also experiences a loss of
lipoglycans under some growth conditions as has been observed
for the Mycobacterium smegmatis Msino1D mutant. (a) The
Mtino1D mutant can only grow like the wild-type strain in medium
that contains at least 77 mM inositol, whereas the Msino1D mutant
only requires 1 mM inositol in the medium for wild-type growth. (b)
When the Mtino1D mutant is incubated in inositol-free medium
there is a decrease in mycothiol levels, but not lipoglycans (PIM,
LM and LAM). The Mtino1D mutant also does not lose viability
under these conditions. Similar results were reported for the
Msino1D mutant when incubated in inositol-free medium at high
density, except that mycothiol was not measured. (c) When the M.
smegmatis Msino1D mutant is incubated in inositol-free medium at
a low dilution (i.e. exponential phase) it experiences a drop in
lipoglycan levels and viability. Mycothiol levels were not measured.
Yellow hexagon, inositol; green hexagon-P, glucose 6-phosphate;
yellow hexagon-P; inositol 3-phosphate; red and yellow phospho-
lipid, PI. These symbols also apply to Figs 2 and 3.
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(Movahedzadeh et al., 2004). The mutant also did not
suffer a loss of viability. Similar results were observed for
an ino1D mutant made in the environmental mycobacter-
ium M. smegmatis as long as it was not actively growing.
The Msino1D mutant did not exhibit a decrease in viability
or lipoglycan levels when incubated in inositol-free media
at a high density, where it was not replicating (i.e.
stationary phase). However, an opposite result was
observed when the Msino1D mutant was diluted to a low
density (i.e. exponential phase) in inositol-free medium. In
exponential phase the Msino1D mutant lost viability over
time, and the levels of cell wall lipoglycans decreased (Fig.
1c) (Haites et al., 2005). It is not clear if the Mtino1D
mutant will lose viability if it is incubated in inositol-free
medium at a lower density (Movahedzadeh et al., 2004). If
an Mtino1D mutant loses viability and lipoglycan produc-
tion during exponential growth, as seen in the Msino1D
mutant, it may experience a decrease in lipoglycans during
infection, which may contribute to its loss of viability and
virulence.
Alternatively, it is also possible that ino1D mutants
constructed in M. smegmatis and M. tuberculosis exhibit
fundamental differences in how they respond to inositol
deprivation. The Mtino1D mutant may simply arrest
growth in inositol-free media, but remain viable, regardless
of the concentration to which it is diluted. M. smegmatis
and M. tuberculosis differ in a number of substantial ways.
While M. tuberculosis is an intracellular parasite, M.
smegmatis is an environmental saprophyte. In addition,
M. smegmatis grows much faster than M. tuberculosis
(doubling time of 4 h for M. smegmatis as opposed to 15–
22 h for M. tuberculosis: Bhatt et al., 1998; James et al.,
2000). In addition, the Msino1D mutant grows as well as
wild-type in much lower concentrations of inositol (1 mM
inositol for Msino1D as opposed to 77 mM for Mtino1D:
Haites et al., 2005). The effect that the loss of de novo
inositol synthesis has on viability and lipoglycan produc-
tion in M. tuberculosis with regard to virulence and viability
in macrophages and mice is not yet understood and further
work in this area is needed.
Mycothiol levels were clearly affected by inositol depriva-
tion in the Mtino1D mutant (Movahedzadeh et al., 2004).
This mutant exhibited a decrease in the level of mycothiol
in inositol-free medium (Fig. 1b), and it was proposed that
a drop in mycothiol might make Mtino1D mutants more
susceptible to the oxidative damage that occurs after the
cells are phagocytosed by macrophages (Movahedzadeh et
al., 2004). However, a role for mycothiol in virulence is not
clear. Some viable mycothiol biosynthetic mutants (mshB
and mshD) are more sensitive than wild-type M. tuber-
culosis strains to oxidative damage, and do not grow well in
macrophages, presumably because of a lowered resistance
to oxidative damage (Newton et al., 2008; Rengarajan et al.,
2005). In contrast to these results, another mycothiol
mutant called mshA, which lacks detectable mycothiol, is
almost fully virulent in SCID and C57BI/6 mice, suggesting
that mycothiol is not required for virulence (Vilche `ze et al.,
2008).
The actual molecular basis for the Mtino1D mutant’s
decrease in virulence is still unclear and much work
remains to be done in order to fully understand it.
Trypanosoma brucei
Trypanosoma brucei is another microbe that must be able
to generate inositol de novo in order to survive.
Paradoxically, T. brucei is able to efficiently import inositol
from the surrounding environment, but if it cannot
synthesize inositol de novo it loses viability (Martin &
Smith, 2006b).
The inability to obtain a homozygous TbINO1 disruption
in T. brucei suggested that this gene is essential. This was
shown to be the case using a strain carrying a conditionally
expressed allele of TbINO1. The two copies of TbINO1
were disrupted only after the cell was transformed with a
plasmid carrying TbINO1 on a tetracycline-inducible
promoter. The resulting strain (INO1-myc
Ti) grew only
when tetracycline was present in the medium (and TbINO1
was transcribed). When tetracycline was absent the INO1-
myc
Ti strain failed to grow, indicating that TbINO1 is
essential (Martin & Smith, 2006b).
Imported inositol is used in synthesis of GPIs at only about
5% the rate of de novo-generated inositol (Martin & Smith,
2006b). Metabolic labelling experiments revealed that
exogenous [
3H]inositol was only poorly incorporated into
glycolipid precursors (A and C) that are used for
synthesizing the GPI anchors (Nagamune et al., 2000)
used to attach essential proteins like variable surface
glycoprotein (VSG) to the plasma membrane (Sheader et
al., 2005). Since [
3H]inositol is very efficiently incorporated
into PI in the membrane, the failure to incorporate label
into VSG is not simply a matter of inadequate inositol
import. In contrast, when [
3H]glucose is used in labelling
experiments, the GPI anchor precursors (glycolipids A and
C) are very efficiently labelled and incorporated into
mature GPI-anchored VSGs. Thus, [
3H]glucose is first
converted to glucose 6-phosphate, which TbIno1p then
converts to inositol 3-phosphate, which is dephosphory-
lated to inositol that is incorporated efficiently into GPI
anchors.
How can such a contradiction be explained? A model put
forth by the authors suggests that there are two pools of
phosphatidylinositol synthase (PIS) that tend to use
inositol derived from the two different main sources:
import and de novo synthesis. One pool of PIS is localized
to the Golgi (Martin & Smith, 2006a) and uses imported
inositol to generate the majority of bulk PI in the cell. The
other PIS is localized to the endoplasmic reticulum (ER)
(Martin & Smith, 2006a), the site where an inositol
monophosphatase (IMPase) is localized (reported as
unpublished results by Martin & Smith, 2006a). The
authors propose that the inositol 3-phosphate synthesized
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as a result the majority of inositol fed into the ER-localized
PIS comes from inositol 3-phosphate. This ER-localized
PIS is proposed to be the source of PI used for GPI anchor
assembly, which also occurs in the ER. If this model is
correct, then it would explain why T. brucei requires
TbINO1 despite its ability to import inositol. It was
suggested by the authors that this mechanism may ensure
that T. brucei always has a ready supply of inositol for the
generation of VSGs. This model is summarized in Fig. 2.
The inositol transporter for T. brucei has not been
investigated. However, work has been done on the inositol
transport characteristics of the closely related parasite T.
cruzi. T. cruzi possesses two inositol transport activities.
One is Na
+-dependent and affects transport at high
concentrations of inositol (5–10 mM), and the other is
Na
+-independent and affects transport at low concentra-
tions (4 mM and below). This suggests that T. cruzi has a
minimum of two types of inositol transporters, at least one
of which is Na
+-dependent and relies on a Na
+ gradient
established across the plasma membrane. Addition of the
Na
+ ATPase inhibitor furosemide partially inhibits both of
these activities. Furosemide does inhibit the Na
+-depend-
ent activity more than the ‘Na
+-independent activity’
(Einicker-Lamas et al., 2000, 2007), but this result calls the
Na
+-independence of the second activity into question.
Inositol transport is energy dependent, as the addition of
energy poisons such as dinitrophenol, azide and KCN also
inhibit it. High concentrations of hexoses, glucose and
mannose do not diminish inositol import, indicating some
specificity for inositol, although this specificity has not
been exhaustively examined.
A number of intriguing questions remain for understand-
ing inositol acquisition in Tryposoma species. It remains to
be seen if T. cruzi, like T. brucei, requires its INO1
homologue for viability. Furthermore, it is not known for
either of these parasites if inositol transport is required for
viability or virulence. If most de novo-synthesized inositol
is used for GPI biosynthesis, will a block in inositol
transport compromise bulk PI biosynthesis and affect
virulence or viability? Answering this question will require
identification of the inositol transporter genes in these
parasites and analysis of their function using gene deletion
approaches.
Leishmania
A related kinetoplastid parasite, Leishmania mexicana, may
share with T. brucei a requirement for de novo inositol
biosynthesis for full wild-type growth and virulence. The
Lmino1D mutant, which is an inositol auxotroph, exhibited
poor growth even in the presence of exogenous inositol up
to 2 mM (Ilg, 2002). In liquid cultures, growing as
promastigotes for over 120 h, the Lmino1D mutant reached
a density of only 25% that of wild-type. The Lmino1D
mutant was also avirulent in a mouse infection model.
Genetic reconstitution experiments revealed that the
Lmino1D::LmINO1 reintegrate strain remained avirulent
and grew to no greater density than the Lmino1D mutant in
the presence of inositol, even though inositol prototrophy
was restored. The reason why virulence and optimal
growth were not reconstituted is not clear. It is possible
that the reconstituted LmINO1 gene is poorly expressed
compared to the wild-type gene. It is also possible that the
avirulence and poor growth phenotypes are genetically
unlinked to the inositol auxotrophy observed in the
Lmino1D mutant. While these results are not conclusive,
they suggest the possibility that L. mexicana, like T. brucei,
may be unable to utilize exogenous inositol efficiently for
GPI synthesis. If this is the case, then utilization of
exogenous inositol appears to be more efficient in L.
mexicana than T. brucei, since L. mexicana exhibits some
limited growth. This is an area for further investigation.
Despite potential functional similarities in the INO1
requirement of Leishmania and Trypanosoma species, the
inositol transporters appear to be quite different. In
Leishmania donovani, inositol is transported by a single
H
+-dependent inositol symporter that relies on the H
+
gradient across the plasma membrane to supply its
energetics. The L. donovani myo-inositol transporter
(MIT) has been cloned, and its predicted structure is very
Fig. 2. The eukaryotic parasite Trypanosoma brucei is able to
import inositol from the environment or synthesize it de novo.
However, according to the current model, inositol imported from
the environment is utilized primarily in bulk phosphatidylinositol (red
and yellow phospholipid) production via a phosphatidylinositol
synthase (PIS) localized to the Golgi complex. Inositol synthesized
de novo is primarily used to generate phosphatidylinositol that is
used for production of glycosylphosphatidylinositols (GPIs). The
de novo-synthesized inositol is believed to be utilized mostly for
GPI production because the IMPase that dephosphorylates
inositol 3-phosphate to inositol is localized to the ER, where GPI
synthesis occurs. Mutants lacking TbINO1 are inviable because of
diminished GPI production.
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1995; Jin & Seyfang, 2003; Seyfang & Landfear, 2000). MIT
may be necessary for full virulence, as a disruption of the L.
dononvani MIT gene resulted in a mutant that grew at a
reduced rate. However, its virulence has not been analysed
in an animal model (Mongan et al., 2004).
Despite its sequence similarity to sugar transporters, MIT is
very specific for inositol and does not appear to recognize
sugar molecules of similar structure such as glucose,
galactose, mannose, fucose, xylose and others (Mongan et
al., 2004). It has been suggested that it may be possible to
exploit this specificity to design toxic analogues of inositol
as antibiotics, since the specificities of the Leishmania MIT
and the human Na
+/inositol transporters SMIT1 and
SMIT2 are different. For example, SMIT1 recognizes fucose
(Hager et al., 1995), and SMIT2 recognizes glucose and
xylose (Coady et al., 2002). However, a complete one-to-
one comparison of substrate specificities for the human
H
+/inositol transporter (HMIT; Uldry et al., 2001) and L.
donovani MIT has not been performed. Nonetheless, an
exciting possibility is that if there is a difference between
the specificities of MIT and HMIT, then it may be possible
to create toxic analogues of inositol that will specifically be
taken up by Leishmania MIT and not by human inositol
transporters.
Other parasites
A potential contrast to the above-mentioned parasites may
exist among the apicomplexan parasites Toxoplasma gondii
and Cryptosporidium parvum. BLAST searches against the
whole-genome sequences of these parasites at EUPath
(http://eupathdb.org/eupathdb/) failed to reveal a homo-
logue for Ino1p. It is possible that T. gondii and
Cryptosporidium do have Ino1p homologues that were
missed in the BLAST search algorithm, or they may have
functional homologues that differ in primary sequence.
However, if indeed these pathogens cannot make inositol
de novo, then they must have mechanisms for acquiring
inositol from the host. This would make inositol
transporters essential for these pathogens, which would
be an interesting contrast to the case of Trypanosoma
brucei, where de novo synthesis is essential.
Candida albicans
Candida albicans appears to be much more versatile than
the above pathogens. During a bloodstream infection it is
able to cause infection with equal efficiency whether it
imports inositol or makes it de novo (Chen et al., 2008). A
C. albicans Caino1D/Caino1D mutant is an inositol
auxotroph. However, unlike T. brucei, L. mexicana or M.
tuberculosis, C. albicans Caino1D/Caino1D mutants are as
virulent as wild-type in a mouse model of systemic
infection. These data initially suggested two possibilities:
(1) C. albicans needs to transport inositol rather than make
it de novo to support an infection; (2) C. albicans can
synthesize or transport inositol with equal efficiency to
support an infection.
C. albicans possesses a high-affinity inositol transporter that,
like the L. donovani transporter, is dependent on a proton
gradient across the membrane (Jin & Seyfang, 2003).
Biochemical analysis of the transport kinetics suggests that
there is only one transporter that is specific for myo-inositol,
and it will not recognize glucose, galactose, mannose,
fructose, fucose, arabinose and xylose. Based on homology
to the S. cerevisiae inositol transporters ScItr1p and ScItr2p
(Nikawa et al., 1991), the C. albicans transporter was
identified and cloned, and the gene was disrupted (Chen
et al., 2008). The Caitr1D/Caitr1D mutant lacked inositol
transport activity compared to the wild-type strain,
indicating that there is only one transporter, as the previous
kinetic studies had suggested (Jin & Seyfang, 2003). Despite
the lack of inositol transport, the Caitr1D/Caitr1D mutant is
fully virulent in a mouse model of systemic infection.
These results indicate that C. albicans is able to acquire
sufficient inositol to support an infection whether it
synthesizes inositol de novo or imports it from the host.
The serum of rats and humans contains 20–100 mM and
61±12.4 mM inositol, respectively (Isaacks et al., 1997;
Kouzuma et al., 2001; Palmano et al., 1977). Mouse serum
is most likely similar, as the Caino1D/Caino1D mutant can
clearly proliferate in the mouse (Chen et al., 2008).
In order to determine if CaIno1p and CaItr1p provide the
only two routes for acquiring inositol from the host, a
conditional double mutant between Caino1D and Caitr1D
was constructed. In C. albicans the MET3 promoter
(PMET3) can be used as a conditional promoter because
PMET3 is strongly activated in the absence of sulfur-
containing amino acids such as cysteine and methionine
(Cys/Met), but in the presence of Cys/Met in the medium
PMET3 is transcriptionally repressed (Care et al., 1999). A
conditional double mutant was constructed by disrupting
both copies of CaINO1 (Caino1D/Caino1D) and one copy
of CaITR1 (Caitr1D). The promoter of the remaining wild-
type copy of CaITR1 was replaced on the chromosome
with the PMET3 promoter. The resulting strain grew at a
wild-type rate in the absence of Cys/Met in the medium,
but did not grow at all in the presence of Cys/Met. These
data indicated that C. albicans has no way to obtain inositol
in vitro aside from de novo synthesis through CaIno1p or
import via CaItr1p. This appears to be true for C. albicans
in the host as well, since in a mouse model for systemic
infection, the conditional double mutant was avirulent and
the mice showed no symptoms of infection, which is
consistent with the hypothesis that the strains could not
survive due to a lack of inositol. The mouse bloodstream
contains sufficient Cys/Met to shut off the PMET3 promoter
(Chen et al., 2008; Rodaki et al., 2006). Even a strain that
contained homozygous mutations for CaINO1 and was
heterozygous for CaITR1 was attenuated for virulence
compared to the wild-type, although it was more virulent
than the conditional double mutant.
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http://mic.sgmjournals.org 1391These data indicate that C. albicans, unlike M. tuberculosis
and T. brucei, is able to acquire inositol by importing it from
the host or by synthesizing it de novo (Fig. 3), and either
mechanism is sufficient to cause a wild-type infection. The
reasonsforthesedifferencesinstrategiesareunclear,butone
large difference between M. tuberculosis and T. brucei and C.
albicans is that C. albicans is a commensal organism. It is
normally found in the gut, oral and/or vaginal tracts of
humans(Calderone,2002).Itsversatilitymayhelp itgrow in
many different host environments. However, this hypothesis
has yet to be tested, as these mutants have not been
examined in the context of vaginal, oral or gut infection
models. In addition, even in the mouse bloodstream
infection model it is not clear which mechanism wild-type
C. albicans prefers to use. For example, does C. albicans
normally use both mechanisms during an infection or does
it favour one method when growing as a commensal and the
other during invasive disease? Is there tissue-specific
expression of these genes so that the method of inositol
acquisition depends on whether the organism grows in the
mucosa, the bloodstream or deep organs? All of these
questions remain to be answered.
How and when CaItr1p and CaIno1p are expressed in the
host will be best understood when regulators of these genes
are identified. Although S. cerevisiae is often a useful guide
for exploring such questions in C. albicans, in this case
there appears to be transcriptional rewiring between these
two yeasts regarding the regulation of their respective
Ino1p homologues. Thus, CaIno1p regulation is an area of
research where much remains to be learned.
The S. cerevisiae transcriptional regulators of ScITR1 and
ScINO1 are well known. Two proteins, ScIno2p and
ScIno4p, form a heterodimeric transcriptional activator
of ScITR1 and ScINO1 as well as other phospholipid
biosynthetic genes. The protein ScOpi1p acts as a repressor
of these same targets by binding to ScIno2p (reviewed by
Chen et al., 2007; Greenberg & Lopes, 1996). Recent studies
have revealed that the C. albicans sequence homologues of
ScIno2p and ScIno4p (CaIno2p and CaIno4p) do not
appear to regulate CaINO1, and may regulate ribosomal
genes (Hoppen et al., 2007). It was even suggested that
CaINO2 and CaINO4 are essential, although these studies
did not conclusively demonstrate this. In addition,
CaOpi1p (a sequence homologue of ScOpi1p) does not
repress transcription of CaINO1. A Caopi1D/Caopi1D
mutant represses CaINO1 in response to exogenous
inositol levels in the same manner as a wild-type strain
(Y. L. Chen & T. B. Reynolds, unpublished data). This is
despite the fact that CaOpi1p can complement a Scopi1D
mutant for regulation of ScINO1 when expressed hetero-
logously in S. cerevisiae (Heyken et al., 2003). Thus, the
actual regulators of CaINO1, CaITR1 and other C. albicans
phospholipid biosynthetic genes remain to be identified.
Identification of basic regulatory components for phos-
pholipid biosynthesis in C. albicans will aid in understand-
ing the regulation of CaIno1p and CaItr1p during an
infection.
It is not known why C. albicans mutants lose viability when
deprived of inositol, but it is very likely due to the
pleiotropic loss of PI and its downstream products,
including GPI anchors (Doering & Schekman, 1996),
membrane phosphoinositides (Strahl & Thorner, 2007)
and sphingolipids (Dickson & Lester, 1999). However, it
remains to be determined precisely what defects cause the
loss of viability during infection.
Cryptococcus neoformans
Cryptococcus neoformans is a fungal pathogen that causes a
fatal meningoencephalitis especially in immunocompro-
mised patients such as those with acquired immune
deficiency syndrome (AIDS) (Casadevall & Perfect, 1998).
Cryptococcus species such as C. neoformans and C. gattii are
believed to enter the host through the inhalation of spores
or desiccated yeast cells that are produced in the
environment. The known environmental niches of C.
neoformans and C. gattii are pigeon guano and eucalyptus
trees, respectively (Casadevall & Perfect, 1998; Idnurm et
al., 2005). This led to the hypothesis that Cryptococcus
species might sporulate in association with plants or trees,
and it was recently demonstrated that substances extracted
from plants can stimulate mating and sporulation in both
C. neoformans and C. gattii (Xue et al., 2007). Interestingly,
the substance with the strongest effect on mating and
sporulation was inositol, which is abundant in plants. If
spore formation by Cryptococcus species is a major source
of infectious propagules for humans, then inositol may be
an environmental cue that promotes human infections by
inducing mating and sporulation.
The mechanism by which inositol promotes mating and
sporulation in Cryptococcus species is not known, but other
Fig. 3. The fungal pathogen Candida albicans can acquire inositol
by de novo synthesis or by importing it, and either mechanism is
sufficient to support wild-type growth in vitro and full virulence.
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acquire a relatively large amount of inositol. C. neoformans
not only generates inositol through a functional inositol-3-
phosphate synthase (CnIno1p), it also catabolizes inositol
as a sole carbon source via an inositol oxygenase (IOase)
activity (Kanter et al., 2003; Molina et al., 1999). Although
some Cryptococcus species repress their IOase activity in the
presence of glucose as a carbon source (Kanter et al., 2003),
C. neoformans expresses IOase activity even when glucose is
present in the medium, and the IOase activity increases
when inositol is the sole carbon source (Molina et al.,
1999). The CnIno1p activity of C. neoformans is much
higher than that of S. cerevisiae. For example, in C.
neoformans the CnIno1p activity is about sevenfold greater
than that of S. cerevisiae when each strain is grown in
medium containing glucose, and lacking inositol. When
excess inositol is added to the medium (75 mM), the
ScIno1p activity is reduced to undetectable levels in S.
cerevisiae,b u ti nC. neoformans the CnIno1p activity level is
similar to that of S. cerevisiae in the absence of inositol.
Only when inositol is used as the sole carbon source is
CnIno1p activity reduced to undetectable levels (Molina et
al., 1999). Bioinformatic analysis predicts that C. neofor-
mans has approximately seven inositol transporters (Xue et
al., 2007). Altogether these data suggest that C. neoformans
has a strong requirement for inositol.
The reasons why C. neoformans has such a strong
requirement for inositol are unclear. In plants inositol is
converted by an IOase activity to glucuronic acid, which
feeds into both the pentose phosphate pathway and the
UDP-glucuronic acid pathway for cell wall biosynthesis
(Loewus et al., 1962; Seitz et al., 2000; Tenhaken & Thulke,
1996). In C. neoformans UDP-glucuronic acid is important
for manufacturing an important virulence factor, the
capsule (Bar-Peled et al., 2004; Griffith et al., 2004;
Moyrand & Janbon, 2004). It has been postulated that
the IOase activity in C. neoformans is supplying glucuronic
acid used to make UDP-glucuronic acid for capsule
biosynthesis (Kanter et al., 2003). However, this does not
appear to be the case, as two different studies have shown
that mutants carrying disruptions of the UGD1 gene, which
encodes the UDP-glucose dehydrogenase that converts
UDP-glucose to UDP-glucuronic acid, completely lack
UDP-glucuronic acid and capsule synthesis (Griffith et al.,
2004; Moyrand & Janbon, 2004). This indicates that in C.
neoformans the IOase does not supply UDP-glucuronic
acid for capsule biosynthesis. It is possible that IOase does
generate glucuronic acid for the pentose phosphate
pathway (Hankes et al., 1969; Kanter et al., 2003; Prabhu
et al., 2005). Whether CnIno1p, IOase or the many inositol
transporter homologues in C. neoformans play a role in
virulence in humans is unclear. The role that inositol plays
in stimulating mating in C. neoformans and its virulence as
a dikaryon in plants (Xue et al., 2007) is also not
understood.
C. neoformans has a tropism for the central nervous system,
which is rich in inositol (Fisher et al., 2002; Heitman et al.,
2006). Tropism for the brain could be driven by the strong
requirement for inositol (Molina et al., 1999). It has also
been suggested that brain tropism is driven by the
abundance of catecholamines in the brain, which can serve
as precursors for biosynthesis of melanin, another virulence
factor (Eisenman et al., 2007; Polacheck et al., 1990). These
factors are not necessarily mutually exclusive. Much work
remains to be done to understand if there is a connection
between Cryptococcus inositol metabolism and brain
tropism.
Prospectus
The broad range of mechanisms by which pathogens
synthesize phospholipids during an infection, and the
surprising strategies that pathogens use to acquire inositol
for PI synthesis while in the host, demonstrate that this
area of research will reveal many fascinating aspects of
host–pathogen biology. It is interesting that two very
different pathogens, Trypanosoma brucei and
Mycobacterium tuberculosis, one an extracellular eukaryotic
parasite and the other an intracellular prokaryotic parasite,
both require inositol biosynthesis for survival and patho-
genesis, respectively. The reasons for this requirement,
however, are quite different. In contrast, the fungal
pathogen Candida albicans requires neither synthesis nor
import exclusively, but can survive using either. These
studies raise many questions about inositol acquisition in
the host. Is the requirement for de novo inositol
biosynthesis found in other mycobacterial pathogens such
as M. leprae and M. ulcerans? Do other parasites besides T.
brucei require de novo inositol biosynthesis for viability or
virulence? Do the apicomplexan parasites Toxoplasma
gondii and Cryptospordium parvum carry functional INO1
homologues? Do other fungal pathogens besides C. albicans
exhibit versatility in their acquisition of inositol?
Another area for future inquiry is whether any of the
enzymes involved in inositol biosynthesis or import may be
useful drug targets. For example, could the requirement for
the Ino1p enzyme be exploited to generate novel
antimicrobials for T. brucei or M. tuberculosis? This enzyme
is admittedly not ideal because a homologue exists in the
host. However, it may be possible to identify a drug that
exhibits specificity for the parasite or bacterial enzyme.
CaIno1p clearly cannot serve as a drug target in C. albicans.
However, there are other enzymes in this fungal pathogen
involved in phospholipid biosynthesis that may be more
promising. For example, the phosphatidylserine synthase
(CaCHO1)o fC. albicans is unique to fungi and not found
in humans (Braun et al., 2005). This has been suggested as
a useful drug target. Similarly, enzymes involved in
phosphatidylcholine biosynthesis have been suggested as
potential antimicrobial drug targets in Plasmodium falci-
parum (Witola et al., 2008). Phospholipid biosynthesis in
these pathogens appears to be a promising area for
exploration.
Inositol acquisition strategies vary among pathogens
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